UNIKE (Hangzhou) Biopharmaceutical Technology Co., Ltd.
UNIKE (Hangzhou) Biopharmaceutical Technology Co., Ltd. stands at the forefront of global biomedicine. With disruptive original technology at its core, the company brings together top global scientific and industrial talent, focusing on the premium track of long-acting protein and peptide innovative drugs. Addressing the industry's core pain points of poor druggability and difficult breakthroughs, and relying on the proprietary ZT technology platform, UNIKE focuses on innovative drug R&D for major diseases — committed to building a global hub for long-acting peptide innovation, filling unmet clinical needs, and safeguarding human health.
2026
Founded
20+
Pipeline Programs
5
Core Platforms
20+
Patents
The company upholds the core philosophy of innovation first and technology as the foundation — tackling pharmaceutical R&D challenges with cutting-edge science, crafting drug quality with rigorous craftsmanship, and connecting global industry resources with open collaboration, creating long-term value for the upgrading of the biopharmaceutical industry and the health of patients worldwide.
Research results from the self-developed ZT technology platform have been published in top international journals and selected as one of Nature's top ten milestone technologies. With patents granted in China, the US, Europe and Japan, the company has built a strong global patent barrier, enabling efficient, low-cost and scalable protein and peptide drug R&D.
Based on the excellent stability and unique 10-site structure of the ZT carrier, our AI atomic-level protein generation model evaluates spatial characteristics of conjugation sites, automatically optimizes linkers, simulates the conformations of complexes, and intelligently produces multivalent multi-target candidate molecules—turning blind site-combination trials into virtual screening, shortening R&D cycles, reducing trial-and-error costs, and opening up new space for complex molecule design.
The company brings together world-class R&D talent. The core team comes from leading institutions such as the German National Research Center for Health and Environment, Charite Berlin, Amgen, and the Chinese Academy of Sciences, combining frontier research capability with proven industrialization experience.
In April 2026, UNIKE (Hangzhou) Biopharmaceutical Technology Co., Ltd. established its operations in Binjiang District, Hangzhou, completed its R&D office and biological research facilities, and began developing innovative long-acting protein and peptide drugs. In June, the company’s project was selected for Binjiang District’s “5050 Plan” for high-level entrepreneurial talent, receiving support under the district’s science and technology innovation policies.
In September 2026, the company completed an angel financing round of tens of millions of RMB, led by Lanhe Capital. The funding will support further development of its core technology platforms and preclinical pipeline, accelerating the discovery and development of innovative peptide drugs.
Established operations in Binjiang District, Hangzhou, completed R&D office and biological research facilities, and launched long-acting protein and peptide drug development.
Selected for Binjiang District’s “5050 Plan” for high-level entrepreneurial talent, receiving regional innovation policy support.
Completed an angel round of tens of millions of RMB led by Lanhe Capital, supporting core platform development and the preclinical pipeline.
UNIKE has a professional R&D team of 20 people, 85% of whom hold master’s or doctoral degrees. Core team members come from leading pharmaceutical companies and research institutions in China and abroad. Five departments—Drug Discovery, Molecular Biology, Fermentation Process Development, Protein Purification, and Pharmacology and Efficacy—cover the key stages of innovative drug development.
20
R&D Personnel
85%
Master’s / PhD Holders
5
R&D Departments
20+
R&D Patents
Investigates disease mechanisms and uses big-data analysis to discover targets, simulate structures, and optimize candidates, driving innovation at the source of drug discovery.
Designs fusion protein molecules, constructs vectors, and performs gene optimization and cloning, providing molecular-level support for protein expression and drug candidate screening.
Develops and optimizes microbial and cell fermentation processes, scales up production, and conducts process quality control to provide consistent upstream material for protein preparation.
Develops recombinant protein expression processes and prepares proteins, performs purification and physicochemical characterization, and supports target discovery and molecular screening.
Establishes in vitro and in vivo efficacy evaluation systems, including cell and animal assays, and investigates candidate activity and mechanisms of action to support molecular screening and target validation.
UNIKE focuses on chronic metabolic diseases, autoimmune diseases, and cancer, where significant unmet clinical needs remain. Using its proprietary long-acting drug technology platforms, the company develops innovative recombinant protein medicines with longer half-lives, more convenient dosing, and improved efficacy, aiming to provide patients with more effective treatment options.
We focus on type 2 diabetes, obesity, non-alcoholic steatohepatitis, and other chronic metabolic diseases. To address frequent dosing and poor treatment adherence, we use our long-acting recombinant protein technology platforms to develop next-generation protein drugs designed to extend circulating half-life, reduce injection frequency, and maintain stable metabolic control, offering more convenient and sustainable treatment options.
To address recurrent disease and the efficacy and safety limitations of existing treatments, UNIKE develops long-acting recombinant protein candidates targeting key disease pathways. These candidates aim to precisely regulate abnormal immune responses, control inflammation and disease progression, optimize dosing intervals, and improve quality of life during long-term treatment.
We address limited target selectivity and heavy dosing burdens in cancer treatment by developing tumor-targeted biologics using long-acting recombinant protein technology. Long-acting molecular designs aim to extend activity in the body, sustain antitumor immune responses or block tumor proliferation signals, and explore improved treatment strategies to meet patients’ clinical needs.